Sinopharm Group Co. Ltd. (01099)

Equity Research Report　|　Industry: Pharmaceutical and Medical Device Distribution and Retail　|　Report Date: September 13, 2026　|　Data as of the Hong Kong market close on September 11, 2026 (Friday); research conducted in mid-September 2026.

This report was automatically compiled by AI based on publicly available information and is for reference only. It does not constitute investment advice.

1. Executive Summary

Sinopharm Group (01099.HK) is China’s largest pharmaceutical and medical device distributor and retailer by scale. China National Pharmaceutical Group, a central state-owned enterprise, holds 57.00% of the total share capital. The company currently exhibits the characteristics of “leading scale, weak growth and low valuation”: FY2025 revenue was RMB 575.168 billion, down 1.60% YoY, while net profit attributable to the parent was RMB 7.155 billion, up 1.50%; 1H2026 revenue was RMB 282.800 billion, down 1.13% YoY, and net profit attributable to the parent was RMB 3.404 billion, down 1.79%. As of the September 11, 2026 close, the share price was HKD 15.36, implying a P/E of approximately 5.8–6.1x, P/B of approximately 0.49–0.50x and a dividend yield of approximately 5.03%–5.14%. However, the share price is already close to the lower end of its 52-week range.

The company’s revenue is highly dependent on pharmaceutical and medical device distribution. In 1H2026, the two businesses together accounted for approximately 92.23% of revenue. Pharmaceutical distribution revenue declined 1.39% YoY, while medical device distribution revenue declined 0.35% YoY. Pharmaceutical retail revenue grew 8.58% YoY and was the relatively strongest business. FY2025 pharmaceutical retail revenue also grew 6.67%, and losses at China Grand Pharmaceutical Pharmacy narrowed substantially. However, the number of China Grand Pharmacy stores declined from 10,516 at end-2023 to approximately 7,975 by mid-2026, indicating that the retail business is currently undergoing contraction and earnings recovery rather than simple expansion.

Profitability remains constrained by volume-based procurement, red- and yellow-label pricing controls, and medical-insurance regulation. The FY2025 gross margin was 7.25%, falling further to 6.74% in 1H2026. Operating margins for pharmaceutical distribution and medical device distribution were 2.42% and 1.77%, respectively. Meanwhile, working-capital usage remains a key constraint: accounts receivable were approximately RMB 220.6 billion in 1Q2026, with receivable days of 141, compared with 103 days for Shanghai Pharmaceuticals and 66 days for Jointown in the same period. This indicates that the company’s scale advantage has not yet fully translated into superior cash-conversion efficiency.

Most market forecasts for FY2026 net profit attributable to the parent are in the range of RMB 7.2–7.7 billion, implying growth of approximately 5% over FY2025. However, analyst views differ significantly, with forecasts ranging from approximately RMB 6.570–7.702 billion and ratings spanning Buy, Outperform, Overweight, Neutral and Hold. Key issues to monitor include whether pharmaceutical distribution revenue can stabilize, recovery in pharmaceutical retail and medical devices, gross-margin stability, and whether receivables management can continue releasing cash flow.

2. Company Overview

2.1 Basic Information

2.2 Core Businesses and Product Mix

• Pharmaceutical distribution — Distributes pharmaceutical products to hospitals, other distributors, retail pharmacies and primary healthcare institutions, while providing distribution, delivery and value-added services; accounted for 72.79% of total revenue in FY2025 and 72.98% in 1H2026
• Medical device distribution — Distributes medical devices to customers and provides installation and maintenance services; became the second-largest segment after acquiring China National Scientific Instruments and Materials, China’s largest medical device distributor, in 2018; accounted for 19.32% of total revenue in FY2025 and 19.25% in 1H2026
• Pharmaceutical retail — Operates pharmaceutical chain stores under the “China Grand Pharmacy” and “Professional Pharmacy” brands; accounted for 6.42% of total revenue in FY2025 and 6.31% in 1H2026
• Other businesses — Distributes laboratory supplies, manufactures and distributes chemical reagents, and produces and sells pharmaceutical products, including proprietary brands such as “HUSH!” and “WOKAI”, mainly through non-hospital channels such as university and third-party testing laboratories

2.3 Position in the Value Chain and Cost-Profit Structure

Sinopharm Group is China’s largest wholesaler and retailer of pharmaceutical products, medical devices and healthcare products, as well as a leading supply-chain service provider. It is a core company of China National Pharmaceutical Group, a central state-owned enterprise. The company operates in the pharmaceutical distribution and circulation segment, for which concepts such as “production capacity” and “resource reserves” are not applicable. Its physical assets consist primarily of a nationwide distribution and delivery network, warehousing and logistics infrastructure, and retail-store network. FY2025 total revenue was RMB 575.168 billion, down 1.6% YoY, and 1H2026 total revenue was RMB 282.800 billion, down 1.13% YoY. The segment mix remained relatively stable, with pharmaceutical distribution accounting for approximately 73%, medical device distribution approximately 19%, and pharmaceutical retail approximately 6%.

• Procurement categories: Finished pharmaceutical products, medical devices and consumables, IVD reagents and healthcare products. Upstream suppliers comprise domestic and overseas pharmaceutical and medical device manufacturers and suppliers. The company also conducts import agency business; import agency revenue was RMB 24 million in 1H2026 and accounted for a very small proportion of revenue.
• Cost structure: Under China’s “two-invoice system”, distributors purchase directly from manufacturers. Procurement costs account for the vast majority of operating costs, and the distribution spread represents gross profit. Volume-based procurement is priced by the state or provincial alliances. The tenth round of national volume-based procurement covered 62 products, with an average price reduction of more than 60% and reductions of up to 90% for certain categories. This compresses margins across the value chain. Distributors, as intermediaries, are essentially price takers and have limited bargaining power over upstream procurement prices.
• Supplier concentration: This research did not identify officially disclosed, cross-verifiable figures for the proportion attributable to the top five suppliers; data are unavailable.
• Related-party procurement: The company is also Sinopharm Group’s procurement and distribution platform and conducts related-party procurement with industrial companies within the Sinopharm system, such as China National Biotec Group and Sinopharm Modern. The exact proportion should be checked in the “Related-Party Transactions” section of the annual report; it was not obtained in this research.
• Customer types: Hospitals, particularly public hospitals; other distributors; retail pharmacies; and primary healthcare institutions.
• End-market structure: According to industry data from Menet, public hospitals accounted for 59.2% of China’s pharmaceutical sales in 2025, down from 63.5% in 2021; retail pharmacies accounted for 31.7%, up from 26.9%; and primary healthcare accounted for 9.1%. The market is shifting from in-hospital contraction to out-of-hospital expansion.
• Customer concentration: This research did not identify officially disclosed, cross-verifiable figures for the combined proportion attributable to the top five customers. An indirect lead from a Snowball user post claimed that hospitals accounted for nearly 70% of receivables and medical insurance for approximately 30%. This is not official disclosure, has not been independently verified and should not be treated as a conclusion.
• Downstream bargaining dynamics: Unlike the annual price reductions seen in the automotive-parts industry, pressure in this sector arises from the extremely long payment cycles of public hospitals. Distributors must first pay suppliers in full and then deliver products to hospitals, while hospital reconciliation and settlement processes are lengthy and affected by fiscal disbursements. Actual payment periods can easily reach 6–10 months; six months is considered very good, while arrears of one to three years are common. A Ministry of Commerce survey of 630 pharmaceutical wholesalers found that the average collection period for receivables from medical institutions was 154 days.
• Severe working-capital usage and downstream bargaining power: Accounts receivable were RMB 205.6 billion as of 2025-12-31 and RMB 220.6 billion in 2026-Q1, with receivable days of 141 in 2026-Q1. This compares with RMB 91.1 billion and 103 days for Shanghai Pharmaceuticals and RMB 37.4 billion and 66 days for Jointown. The combined receivables of Sinopharm, Shanghai Pharmaceuticals and China Resources in 2025 exceeded RMB 380 billion. Dividing receivables of RMB 205.6 billion as of 2025-12-31 by net profit attributable to the parent of RMB 7.155 billion gives approximately 28.7x. The industry’s average profit margin was only 1.5% in 2024. However, 2025 showed signs of improvement: net cash generated from operating activities was RMB 14.138 billion, nearly RMB 2.6 billion higher than the previous year; the increase in receivables narrowed significantly; the debt-to-asset ratio declined by 2.12 percentage points; and the company stated that it had launched a dedicated receivables-management campaign focused on reducing receivables outstanding for more than one year. In June 2026, Sinopharm’s Wenzhou subsidiary transferred receivables from Wenzhou Medical University Eye Hospital to China Merchants Bank’s Wenzhou branch through non-recourse factoring. This was reportedly the first factoring transaction in China based on pharmaceutical traceability codes, supported by a RMB 300 million special credit facility and an initial drawdown of RMB 9.21 million. If broadly adopted, the model could partially remove receivables from the balance sheet.
• Concentration data: This research did not identify cross-verifiable official figures for either the top-five supplier share or the combined top-five customer share. The latest annual report should be consulted. The available related concentration information is based on market share: the four leading pharmaceutical distributors together account for more than 35% of the market. The source is of moderate authority and does not distinguish the individual shares of each company.

Sinopharm operates in the middle of the smile curve, namely the circulation and distribution segment, earning distribution spreads. It is a typical low-margin, midstream processing and distribution business. The industry’s average profit margin was only approximately 1.5% in 2024, while the company’s net margin attributable to the parent has historically been around 2.5% and its gross margin approximately 8.0%–8.6%. It faces pressure from both upstream manufacturers and volume-based procurement pricing mechanisms, and from downstream public hospitals’ extremely long payment cycles. It has little purchasing or sales pricing power.

Further margin improvement depends not on price increases but on four avenues: first, upgrading the product mix and securing distribution rights for innovative drugs, devices and higher-value products; sales of products included in national negotiations and innovative drugs grew 27% and 30% YoY, respectively, in 1H2026 according to management; second, optimizing the business mix by increasing the proportion of higher-value-added services such as CSO pharmaceutical marketing services, SPD smart device supply chains and third-party logistics, as well as higher-margin professional pharmacies; third, improving working-capital efficiency through dedicated receivables management and tools such as non-recourse factoring; and fourth, achieving cost dilution through scale and integrated operations. However, if volume-based procurement and medical-insurance cost controls continue to deepen, structural pressure on midstream distribution spreads will persist and margin improvement remains uncertain.

3. Financial Data and Valuation Analysis

3.1 Recent Operating Performance

The FY2025 financial statements are presented in RMB and represent the latest annual report; 1H2026 is the latest financial reporting period and the company did not pay an interim dividend. The FY2025 final dividend was RMB 0.69 per share before tax, subject to shareholder approval. Basic and diluted EPS were RMB 2.29, compared with RMB 2.26 in the previous year, up 1.33%. Gross profit was RMB 41.672 billion, down 5.84%, and gross margin was 7.25%. Net operating cash inflow was RMB 14.138 billion and the debt-to-asset ratio was 65.63%, down 2.12 percentage points YoY. 1H2026 basic EPS was RMB 1.09, compared with RMB 1.11 in 1H2025, down 1.80%. Gross profit was RMB 19.071 billion and gross margin was 6.74%, compared with 7.11% in 1H2025, down 0.37 percentage points. The debt-to-asset ratio was 66.29%, up 0.66 percentage points from end-2025. Net cash used in operating activities was RMB 23.763 billion, and cash and cash equivalents at period-end were RMB 31.045 billion, down RMB 17.751 billion from end-2025. FY2025 segment revenue: pharmaceutical distribution RMB 435.392 billion, 72.79% of total revenue and down 2.02%; medical device distribution RMB 115.538 billion, 19.32% and down 2.02%; pharmaceutical retail RMB 38.383 billion, up 6.67%, with China Grand Pharmacy losses narrowing substantially. 1H2026 segment revenue: pharmaceutical distribution RMB 215.496 billion, 72.98% and down 1.39%; medical device distribution RMB 56.854 billion, 19.25% and down 0.35%; pharmaceutical retail revenue up 8.58% YoY. Q1 2026 also disclosed cash and cash equivalents of RMB 36.366 billion, short-term borrowings of RMB 69.248 billion, long-term borrowings of RMB 1.044 billion and bonds payable of RMB 2.998 billion as of 2026-03-31. Sources: hkexnews.hk, company IR, stcn.com, finance.eastmoney.com, wap.stockstar.com, etf.etnet.com.hk and Goldman Sachs research via cn.investing.com.

Revenue has continued to decline: FY2025 revenue fell 1.60% YoY, 1H2026 declined 1.13%, Q1 2026 declined 0.6%, and Q2 2026, based on broker estimates, declined 1.6%. Overall, revenue appears to have stabilized at a low level but has not shown a clear rebound. Profit has fluctuated at low-single-digit rates: FY2025 net profit attributable to the parent increased 1.50%, while 1H2026 turned to a decline of 1.79%, or 2.95% including minority interests, mainly due to lower gross margin. The 1H2026 gross margin was 6.74%, down 0.37 percentage points YoY, while Q2 2026 gross margin was 7.05%, below 7.46% in the same period of 1H2025. Pharmaceutical and device distribution revenue both declined modestly, while pharmaceutical retail continued to grow rapidly. China Grand Pharmacy losses narrowed substantially. Net cash used in operating activities was RMB 23.763 billion in 1H2026, and period-end cash and cash equivalents fell RMB 17.751 billion from end-2025. Management expected pharmaceutical distribution sales to remain flat YoY in 2026, with medical device distribution and retail recovering further and recording positive growth. It guided for double-digit YoY growth in retail pharmacy revenue in 2026. A search result showing “1H2026 revenue of RMB 36.266 billion, net profit attributable to the parent of RMB 606 million, down 8.97%” relates to Sinopharm Group’s subsidiary Sinopharm Accord Pharmaceutical (A+B shares), not the consolidated group, and should not be confused with the group figures.

3.2 Earnings Forecasts

The FY2026 forecasts below were compiled from the etnet earnings forecast page (stocks.etnet.hk/www/sc/stocks/realtime/quote_profit.php?code=1099; real-time quotation updated 2026-09-02 18:00). They are individual broker forecasts rather than a strict multi-institution consensus average. Most FY2026 forecasts for net profit attributable to the parent are concentrated at RMB 7.2–7.7 billion, with an average of approximately RMB 7.5 billion, implying growth of approximately 5% over FY2025 net profit of RMB 7.155 billion. Daiwa is significantly below peers. Some data were updated before the 1H2026 results released on 2026-08-24 and should be used cautiously. The etnet aggregation page may lag, and individual citations should be checked against the original research reports. Complete multi-institution FY2027/FY2028 consensus forecasts were not fully cross-verified in this research memorandum. The etnet table clearly displays only FY2026, while only Daiwa’s FY2027–FY2028 EPS growth forecasts and Goldman Sachs’ forecast reductions were available for reference. Daiwa downgraded the stock from Outperform to Hold and cut its target price from HKD 21 to HKD 18 on 2026-07-09/10. Citi cut FY2026–FY2027 revenue forecasts by 3% and 4%, respectively, and EPS forecasts by 5% each, while reducing its target price from HKD 23 to HKD 22.8 and maintaining Buy. Goldman Sachs cut its target price from HKD 19.07 to HKD 18.46 on 2026-08-26 and maintained Neutral.

3.3 Valuation and Institutional Ratings

As of the September 11, 2026 close, with some sources dated September 2, the share price was HKD 15.36–15.37. Total market capitalization was approximately HKD 47.93 billion, calculated using total share capital of 3,120,656,191 shares. H-share market capitalization was approximately HKD 20.61 billion. Valuation multiples were approximately 5.87–5.96x on a trailing P/E basis, approximately 6.06x on a static FY2025 P/E basis, and 0.49x on an MRQ P/B basis. Net asset value per share was approximately RMB 2.69–2.73. The trailing dividend yield was 5.14% according to Dongfangcaifu and moomoo, versus 4.65% under the etnet methodology. Trailing dividends per share were HKD 0.79, with a payout ratio of approximately 30.1%–30.6%.

The 52-week high and low were HKD 21.55 and HKD 15.17 according to moomoo and Baidu. Another source dated 2026-07-02 showed HKD 22.34 and HKD 15.28, while Morningstar showed HKD 15.22–22.34. The 52-week high therefore differs modestly by source, and the current share price is close to the 52-week low.

Based on a rough forward-valuation calculation, total market capitalization of approximately HKD 47.9 billion is equivalent to approximately RMB 44.1 billion at HKD 1.00 ≈ RMB 0.92. Relative to FY2025 net profit attributable to the parent of RMB 7.155 billion, the static P/E is approximately 6.2x. Relative to the broker forecast midpoint of approximately RMB 7.5 billion for FY2026, the forward P/E is approximately 5.9x, consistent with the market P/E of approximately 5.9x. Target prices range from HKD 17.00 to HKD 25.70, with a simple average of approximately HKD 21 based on more than ten etnet-listed institutions. Ratings are predominantly positive, with approximately seven Buy/Outperform/Overweight/Outperform-equivalent ratings and three Neutral/Hold ratings. Overall, the company has the characteristics of a low-valuation, low-growth pharmaceutical-distribution leader: P/B is only 0.49x and dividend yield is approximately 5%, but revenue has declined for several consecutive periods and net profit growth remains in the low single digits. Target-price dispersion is very wide and source definitions differ. Investors should rely on the latest individual research report rather than aggregation-page figures. Share price, market capitalization, P/E and dividend yield reflect data around September 11, 2026. Differences among moomoo, Baidu, Morningstar and etnet include timing and denominator conventions. The 1H2025 net profit attributable to the parent differs slightly at approximately RMB 3.458–3.466 billion depending on the treatment of minority interests, without affecting the conclusion of a 1.79% YoY decline. Hong Kong stocks use mainland China’s color convention, with red indicating gains and green indicating declines; this section does not contain color references.

4. Recent News and Announcements

4.1 Security Confirmation: 01099.HK Is Sinopharm Group Co. Ltd.

01099.HK corresponds to Sinopharm Group Co. Ltd., not Wong’s International (00099) or IRC (01029). HKEXnews official documents clearly show “Stock Code: 01099” and the company name, which is also confirmed on the company IR page. The company is China’s largest wholesaler and retailer of pharmaceutical products, medical devices and healthcare products, and a core subsidiary of Sinopharm Group. It was established in 2003 and listed in Hong Kong in September 2009. Its segments comprise pharmaceutical distribution, approximately 71%–73%; medical device distribution, approximately 20%–22%; pharmaceutical retail, including China Grand Pharmacy and Professional Pharmacy, approximately 5.8%–5.9%; and other businesses. The latest verifiable information retrieved was from approximately late August 2026.

4.2 FY2025 Results Announcement

Total revenue was RMB 575.168 billion, down 1.60% YoY. Profit for the year was RMB 10.834 billion, up 3.94%, and net profit attributable to the parent was RMB 7.155 billion, up 1.50%. Basic and diluted EPS were RMB 2.29, compared with RMB 2.26 in the previous year, up 1.33%. Net operating cash inflow was RMB 14.138 billion, an increase of RMB 2.592 billion YoY. The debt-to-asset ratio was 65.63%, down 2.12 percentage points. Pharmaceutical retail revenue increased 6.67% and China Grand Pharmacy losses narrowed substantially. The board proposed a final dividend of RMB 0.69 per share before tax. A media summary incorrectly stated revenue as “RMB 575,167.88 billion”; this was a decimal-point error. The correct figure is RMB 575.168 billion.

4.3 H1 2025 Results Announcement

Revenue was RMB 286.043 billion, down 2.95% YoY; net profit attributable to the parent was RMB 3.466 billion, down 6.43%; EPS was RMB 1.11; no interim dividend was paid. Segment revenue comprised pharmaceutical distribution of RMB 218.527 billion, down 3.52% and representing 73.62%; medical device distribution of RMB 57.053 billion, down 2.46% and representing 19.22%; pharmaceutical retail of RMB 17.162 billion, up 3.65% and representing 5.78%; and other businesses of RMB 4.076 billion, down 0.71%. Gross margin was 7.11%, down 0.34 percentage points, and operating profit was RMB 7.446 billion, down 9.44%. China Grand Pharmacy had 8,591 stores, a net reduction of 978 from end-2024, while Professional Pharmacy had 1,516 stores, a net reduction of 128. Professional Pharmacy maintained double-digit same-store growth.

4.4 9M2025 Data

Revenue for the first three quarters was RMB 431.479 billion, down 2.47% YoY. Net profit attributable to the parent was RMB 5.307 billion, up 0.53% YoY, indicating that the profit decline had stabilized modestly.

4.5 1Q2026 Data

Q1 2026 revenue was RMB 140.7658 billion, compared with RMB 141.6616 billion in Q1 2025, representing a decline of approximately 0.6%. This figure came from a single Moomoo source and should be verified against the company’s quarterly announcement. Moomoo listed the compilation date for its “2026 H1 Results Summary” as 2026/08/21, but the specific figures were not obtained in this research and remain an unverified gap. Investors should consult the August 2026 interim-results announcement on HKEXnews.

4.6 FY2024 Comparison

Revenue was RMB 584.508 billion, down 2.02%, and net profit attributable to the parent was RMB 7.050 billion, down 22.14%. Medical device distribution, down 9.44%, was the principal drag.

4.7 Chairman Replacement and Management Changes

For “work-arrangement reasons”, Zhao Bingxiang resigned on November 28, 2025 as non-executive director, chairman, chairman of the Nomination Committee, chairman of the Strategy and Investment Committee, member of the Legal, Compliance and ESG Committee, authorized representative and from other positions. Feng Rongli simultaneously resigned as non-executive director and from the Remuneration Committee and Nomination Committee. The resignations became effective upon appointment of successors by the general meeting. On the same day, the board elected Jin Bin as chairman and authorized representative and proposed appointing Jin Bin and Li Ying as non-executive directors. Zhao Bingxiang had joined Sinopharm Group in March 2024 and became chairman of the company in September 2024, leaving after slightly more than one year.

4.8 EGM Results

The extraordinary general meeting was held at Room 1401, Sinopharm Group Building, No. 385 Longhua East Road, Huangpu District, Shanghai. Four ordinary resolutions were approved: appointing Jin Bin as non-executive director, Yang Binghua as executive director, Ma Yue as non-executive director and Li Ying as non-executive director. Approval votes exceeded 95% in each case. Shares represented at the meeting totaled 2,656,080,900, or 85.11% of issued shares. The board composition included executive directors Lian Wanyong and Yang Binghua; non-executive directors Jin Bin, Chen Qiyu, Zu Jing, Xing Yonggang, Ma Yue, Chen Yuqing, Wen Deyong and Li Ying; and independent non-executive directors Li Peiyu, Wu Delong, Yu Weifeng, Shi Shenghao and Chen Weiru.

4.9 FY2024 Final Dividend

The final dividend was RMB 0.68 per share, equivalent to HKD 0.739 at an exchange rate of HKD 1.00 ≈ RMB 0.92. It was approved at the AGM on June 12, 2025, went ex-dividend on June 16, 2025, had a record date of June 23, 2025 and was paid on August 12, 2025.

4.10 FY2025 Final Dividend

The final dividend was RMB 0.69 per share, equivalent to approximately HKD 0.78–0.79. It was announced on 2026/03/20, approved by shareholders on 2026/06/18, went ex-dividend on 2026/06/23, had a record date of 2026/06/30 and was paid on 2026/08/18. Withholding tax was 10% for non-resident enterprises and individuals and 20% for mainland individual investors trading through Stock Connect. No interim dividend was paid for H1 2025, and no quarterly dividends were paid.

4.11 Repurchase Authorization and Shareholder Movements

At the June 18, 2026 AGM, shareholders authorized the board to repurchase up to 10% of the issued H shares and issue new shares representing up to 20% of the total nominal value of each class of issued shares. This research found no announcement that the company had actually repurchased H shares in 2026. The authorization should continue to be monitored through HKEXnews Next Day Disclosure Returns.

Lazard Asset Management LLC held 118,821,504 shares, or 8.86%, as of 2025/02/28, at an average price of HKD 19.58. According to Zhitong Finance, Lazard acquired 959,600 shares on September 4, inferred to be 2025/09/04, at an average price of approximately HKD 15.6782, involving approximately HKD 15.0448 million. Its holdings subsequently rose to approximately 188 million shares, or approximately 14% on an H-share basis. J.P. Morgan Chase & Co. sold 1,221,708 shares on 2025/02/18 at an average price of HKD 19.8733 and held a long position of 106,820,423 shares, or 7.96%, a short position of 18,337,040 shares, or 1.36%, and 16,216,099 shares available for lending, or 1.20%. BlackRock disclosed in December 2025 that its long position included direct corporate interests of 81,666,397 shares and a short position of 3,130,000 shares, or 0.23%, as well as long and short positions in unlisted cash-settled derivatives. These disclosure dates range from February to December 2025 and do not represent the latest holdings as of the research date. Percentages generally use H shares as the denominator and should not be directly compared with percentages based on total share capital.

5. Share Price Performance and Technical Analysis

5.1 Price Overview

5.2 Technical Indicators

5.3 Short-Term Outlook, Next Week, Scenario Analysis for Reference Only

6. Industry Structure and Competitor Analysis

6.1 Industry Conditions

China’s pharmaceutical distribution industry is shifting from a “channel economy” to a “service economy”. Industry concentration is rising rapidly and an oligopolistic structure is emerging. Leading companies are upgrading their value proposition by restructuring their business models from earning distribution spreads to earning service fees. In 2025, China’s pharmaceutical logistics costs totaled RMB 101.99 billion, including RMB 26.78 billion in pharmaceutical cold-chain logistics costs. The end-market structure is shifting from in-hospital contraction to out-of-hospital expansion: public hospitals accounted for 59.2% of pharmaceutical sales in 2025, retail pharmacies 31.7% and primary healthcare 9.1%. Common industry pressures include volume-based procurement, red- and yellow-label price controls, medical-insurance cost controls, and working-capital usage caused by long payment cycles at public hospitals. A 2024 Ministry of Commerce survey showed average collection periods of 154 days for receivables from medical institutions.

6.2 Competitive Landscape

• The four leading pharmaceutical distributors together account for more than 35% of the market, and concentration is rising toward an oligopolistic structure.
• Sinopharm is the industry’s largest company and China’s largest wholesaler and retailer of pharmaceutical products, medical devices and healthcare products, as well as a leading supply-chain service provider.
• Main listed competitors include Shanghai Pharmaceuticals, China Resources Pharmaceutical and Jointown. Sinopharm’s receivable days of 141 in 2026-Q1 were significantly longer than Shanghai Pharmaceuticals’ 103 and Jointown’s 66.
• The business model is shifting from a “channel economy” to a “service economy”. Leading companies are using CSO, SPD and third-party logistics service fees to supplement or replace pure distribution spreads and are exploring an ecosystem model integrating healthcare, pharmaceuticals, insurance and technology.
• In June 2026, Sinopharm’s Wenzhou subsidiary completed China’s first non-recourse factoring transaction based on pharmaceutical traceability codes, supported by a RMB 300 million special credit facility and an initial RMB 9.21 million drawdown. Wider adoption could alleviate industry-wide receivables pressure.
• The tenth round of national volume-based procurement covered 62 products, with average price reductions exceeding 60% and some categories reaching 90%. As price takers, distributors face structural pressure on spreads.

6.3 Main Competitors

Sinopharm is China’s largest pharmaceutical-distribution company by revenue, with pharmaceutical distribution accounting for approximately 73%, medical device distribution approximately 19%, pharmaceutical retail approximately 6% and other businesses making up the balance. Scale and its nationwide distribution network are its key competitive advantages. However, like its peers, it occupies a midstream position squeezed by both upstream and downstream. Upstream pricing is constrained by volume-based procurement and manufacturers, while downstream cash is tied up by public hospitals’ lengthy payment cycles. Its receivable days of 141 and receivables of RMB 220.6 billion in 2026-Q1 were the heaviest among the disclosed comparable companies, significantly worse than Shanghai Pharmaceuticals and Jointown. Working-capital efficiency is therefore a relative weakness.

The structural pressures of procurement price cuts, medical-insurance cost controls and slow hospital collections apply to all four leading companies. Differentiation depends on working-capital management and progress in the transition toward services. Sinopharm is using receivables management, innovative factoring and higher-value-added services such as CSO, SPD and third-party logistics to improve earnings quality. Its RMB 14.138 billion net operating cash inflow in 2025 was a positive signal. However, top-five customer and supplier concentration, as well as 2024 gross and net margins, were unavailable in this research memorandum, limiting the completeness of peer comparisons. China Grand Pharmacy stores declined from 10,516 at end-2023 to approximately 7,975 by mid-2026, indicating retail contraction rather than expansion; the figures came from different sources and should be checked against the latest annual report.

7. Risk Factors

• Policy-driven pricing pressure and gross-margin decline: Volume-based procurement, red- and yellow-label pricing controls and medical-insurance regulation continue to compress distribution spreads. Gross margin declined from 7.25% in FY2025 to 6.74% in 1H2026, while pharmaceutical and medical device distribution operating margins fell to 2.42% and 1.77%. Further policy pressure could cause profit growth to lag revenue.
• Hospital collections and working-capital risk: Receivables were approximately RMB 220.6 billion in 2026-Q1 and receivable days were 141, versus 103 for Shanghai Pharmaceuticals and 66 for Jointown. Net cash used in operating activities was RMB 23.763 billion in 1H2026, while cash and cash equivalents fell RMB 17.751 billion from end-2025. Continued delays in public-hospital settlement could increase financing and liquidity pressure.
• Stagnation in core distribution businesses: Pharmaceutical distribution accounted for 72.98% of 1H2026 revenue and declined 1.39% YoY. Medical device distribution accounted for 19.25% and declined 0.35%. Group revenue fell 1.60% in FY2025 and 1.13% in 1H2026. If distribution cannot stabilize, retail and other businesses may not be sufficient to restore group-wide growth.
• Retail recovery below expectations: Pharmaceutical retail revenue grew 6.67% in FY2025 and 8.58% in 1H2026, and China Grand Pharmacy losses narrowed sharply. However, store count declined from 10,516 at end-2023 to approximately 7,975 by mid-2026, showing that the business remains in an adjustment phase. Store contraction or insufficient Professional Pharmacy growth could weaken the expected second growth curve.
• Earnings-forecast and valuation-reset risk: FY2026 net profit forecasts range from approximately RMB 6.570–7.702 billion. Daiwa downgraded the stock to Hold, while Goldman Sachs maintained Neutral and cut its target price to HKD 18.46. If results fall below the prevailing forecast range of approximately RMB 7.2–7.7 billion, the current P/E of approximately 5.8–6.1x and P/B of approximately 0.49–0.50x may not immediately lead to a valuation recovery.
• Cash-flow and debt-management risk: The debt-to-asset ratio rose from 65.63% in FY2025 to 66.29% in 1H2026. Q1 2026 short-term borrowings were approximately RMB 69.248 billion, compared with cash of approximately RMB 36.366 billion. Slower receivables collection or continued negative operating cash flow could increase short-term funding and financing-cost pressure.
• Corporate-governance and management-change risk: Chairman Zhao Bingxiang resigned in November 2025 for work-related reasons and was succeeded by Jin Bin, who was appointed a non-executive director at the December 2025 EGM. Changes to management and the board could affect strategic continuity while distribution transformation, retail adjustment and receivables management remain at critical stages.

8. Conclusion and Outlook

Sinopharm’s growth thesis is based primarily on structural optimization built on scale and network advantages rather than on traditional high revenue growth. The company has nationwide distribution, warehousing, logistics and retail networks and is transitioning from a “channel economy” to a “service economy”. It is focusing on innovative drug and device distribution, CSO pharmaceutical marketing services, SPD smart supply chains and third-party logistics. In 1H2026, sales of products included in national negotiations and innovative drugs increased 27% and 30% YoY, respectively, while pharmaceutical retail revenue maintained rapid growth, supporting improvement in the business mix.

Cash flow and working-capital management will determine whether earnings quality improves. Net operating cash inflow was RMB 14.138 billion in FY2025, an improvement over the previous year, and the company launched dedicated receivables management. In June 2026, Sinopharm’s Wenzhou subsidiary completed non-recourse factoring based on pharmaceutical traceability codes, supported by a RMB 300 million special credit facility and an initial RMB 9.21 million drawdown. If receivables reduction and factoring can be scaled up, they may alleviate the impact of slow hospital collections. However, net cash used in operating activities turned to RMB 23.763 billion in 1H2026, and the sustainability of any improvement requires confirmation in subsequent financial reports.

Overall, the company combines industry leadership, central state-owned-enterprise backing, low valuation and a dividend yield of approximately 5%. However, consecutive revenue declines, falling gross margin and substantial receivables usage make it more of a defensive, low-valuation and low-growth distribution leader. Continued valuation recovery depends on stabilization in distribution, whether the services transition can enhance profitability, and whether growth in retail and medical devices can offset the spread pressure from volume-based procurement and medical-insurance cost controls. This conclusion does not constitute a recommendation to buy or sell.

Data Sources

• 01099 Sinopharm - Free Real-Time Stock Quote - Company Business
• Sinopharm Group Co. Ltd.
• Sinopharm Group Co. Ltd.
• Sinopharm Group Co Ltd (01099)
• Sinopharm Group Co. Ltd.
• Sinopharm Group Co Ltd 01099 Action
• Wong’s International (0099.HK) Stock Price, News and History
• 1099.HK SINOPHARM - Company Information
• 01099.HK
• Xiaocaiyuan International Holding Ltd. (0999.HK)
• Sinopharm Group (01099) Company Overview
• Sinopharm Group: Results in Line with Expectations
• Sinopharm Group (01099): 2026 Interim Results Announcement
• Sinopharm Group: FY2025 Net Profit Attributable to Parent RMB 7.155 Billion
• CITIC Construction Investment Maintains Buy Rating on Sinopharm Group
• Sinopharm Group: 2026 Interim Results Announcement
• Sinopharm Group Company Information
• Sinopharm Group: Pharmaceutical Retail Business
• Sinopharm Group FY2025 Results
• Sinopharm Group FY2025 Results
• Sinopharm Group Financial Results Summary
• Sinopharm Group Financial Ratios
• Sinopharm Group Earnings History
• Sinopharm Group Interim Earnings
• Sinopharm Group Income Statement
• Sinopharm Group Income Statement
• Sinopharm Group
• Sinopharm Group Interim Income Statement
• Sinopharm Group Financial Summary
• Sinopharm Group Earnings
• Four Leading Pharmaceutical Distributors Account for More Than 35% of Market Share
• Four Major Pharmaceutical Companies’ 2025 Interim Reports
• The Midstream Distribution Revolution
• 2025 Pharmaceutical Distribution Industry Competition
• Jointown 2025 Annual Report Summary
• Pharmaceutical Distribution: Service Restructuring
• Pharmaceutical Distribution: Service Restructuring
• Southern Finance
• Kearney Management Consulting Industry Analysis
• Pharmaceutical Distribution Industry Report
• National Healthcare Security Administration: Hospital Collection Problems
• National Healthcare Security Administration: New Model
• Pharmaceutical Traceability-Code Factoring
• From Scale King to Efficiency King
• Sinopharm Group 2025 Bond Annual Report
• Snowball Financial Discussion
• Sinopharm Group Operating Analysis
• Pharmaceutical Receivables Factoring
• Pharmaceutical Receivables Factoring Podcast
• Sinopharm Group’s Hidden Inflection Point
• Sinopharm Group Co.
• Sinopharm Group 2024 Interim Report
• Sinopharm Group Co. Ltd.
• Sinopharm Group Earnings
• Sinopharm Group Company Business
• Sinopharm Group Basic Data
• Sinopharm Group Overview
• 01099 Sinopharm
• HKEX DI Search
• 01099 Sinopharm
• Lazard Increases Sinopharm Holdings
• Sinopharm: 1H Net Profit Attributable to Parent RMB 3.404 Billion
• Sinopharm: First-Half Net Profit Declined 8.97%
• Sinopharm Group 1H2026 Results
• Sinopharm Group Interim Results
• Sinopharm Accord 1H2026 Report
• Sinopharm Group Interim Results Summary
• Sinopharm Group Bond Report
• Sinopharm: First-Half Net Profit Declined 8.97%
• Sinopharm Group 1H2026 Results
• Goldman Sachs Cuts Target Price
• Daiwa Downgrades Sinopharm to Hold
• Daiwa Downgrades Sinopharm
• Yuanta Securities (Hong Kong)
• Daiwa Downgrades Sinopharm
• Daiwa: Sinopharm Downgraded to Hold
• Sinopharm Earnings Forecast
• Daiwa Research on Sinopharm
• Sinopharm FY2025 Results
• Sinopharm FY2025 Revenue and Profit
• Sinopharm FY2025 Results Summary
• Sinopharm Annual Results and Dividend
• Sinopharm Dividend Proposal
• Sinopharm Final Dividend
• Sinopharm FY2025 Dividend
• Sinopharm Share Price Movement
• Sinopharm Annual Results
• Sinopharm Board Changes
• Sinopharm EGM Results
• Sinopharm Chairman Resignation
• Sinopharm EGM Voting Results
• Sinopharm EGM and Board Changes
• FY2025 Dividend Announcement
• FY2025 Final Dividend Proposal
• Sinopharm AGM Notice
• Sinopharm Dividend History
• Sinopharm FY2025 Distribution Plan
• Sinopharm FY2025 Results and Dividend
• Sinopharm Historical Share Price
• Sinopharm Block Trade
• Sinopharm Trading Analysis
• Sinopharm Latest Price
• Sinopharm Stock Quote
• Sinopharm Yahoo Finance
• Sinopharm Stock Overview
• Free Real-Time Technical Analysis
• AASTOCKS Sinopharm News
• Sinopharm Company Profile
• Sinopharm Valuation Statistics
• AASTOCKS
• Individual Stock Research
• Sinopharm Cash Flow
• Sinopharm Technical Analysis
• Sinopharm Technical Analysis
• Sinopharm Technical Analysis
• AASTOCKS Chart
• Sinopharm
• Sinopharm Quantitative Analysis
• Sinopharm Quantitative Research
• Sinopharm Articles
• Sinopharm Securities Star
• CITIC Securities Warrant Terms
• Sinopharm Share Price Commentary
• CITIC Securities Warrant Terms
• Hong Kong Stock Holdings
• Hong Kong Stock Holdings
• Sinopharm Company Developments
• Sinopharm Information
• Sinopharm Block Trade
• Sinopharm Discussion
• Sinopharm Block Trade

This report was automatically retrieved, compiled and generated by AI based on publicly available information. Information is current as of the Hong Kong market close on September 11, 2026 (Friday), with research conducted in mid-September 2026. Timing differences may exist. Specific figures should be checked against the company’s formal announcements and authoritative data terminals. This report is for information and research reference only and does not constitute investment advice. Investors should make independent judgments and bear their own investment risks.